Modelling pyruvate dehydrogenase under hypoxia 1 and its role in cancer metabolism by Angione, Claudio & Eyassu, Filmon
rsos.royalsocietypublishing.org
Research
Cite this article: Eyassu F, Angione C. 2017
Modelling pyruvate dehydrogenase under
hypoxia and its role in cancer metabolism.
R. Soc. open sci. 4: 170360.
http://dx.doi.org/10.1098/rsos.170360
Received: 20 April 2017
Accepted: 25 September 2017
Subject Category:
Computer science
Subject Areas:
systems biology/computational
biology/mathematical modelling
Keywords:
constraint-based models, flux balance
analysis, cancer metabolism, pyruvate
dehydrogenase, hypoxia
Author for correspondence:
Claudio Angione
e-mail: c.angione@tees.ac.uk
Electronic supplementary material is available
online at https://doi.org/10.6084/m9.figshare.
c.3900499.
Modelling pyruvate
dehydrogenase under
hypoxia and its role in
cancer metabolism
Filmon Eyassu and Claudio Angione
Department of Computer Science and Information Systems, Teesside University,
Middlesbrough, UK
CA, 0000-0002-3140-7909
Metabolism is the only biological system that can be fully
modelled at genome scale. As a result, metabolic models have
been increasingly used to study the molecular mechanisms
of various diseases. Hypoxia, a low-oxygen tension, is a
well-known characteristic of many cancer cells. Pyruvate
dehydrogenase (PDH) controls the flux of metabolites between
glycolysis and the tricarboxylic acid cycle and is a key
enzyme in metabolic reprogramming in cancer metabolism.
Here, we develop and manually curate a constraint-based
metabolic model to investigate the mechanism of pyruvate
dehydrogenase under hypoxia. Our results characterize the
activity of pyruvate dehydrogenase and its decline during
hypoxia. This results in lactate accumulation, consistent with
recent hypoxia studies and a well-known feature in cancer
metabolism. We apply machine-learning techniques on the
flux datasets to identify reactions that drive these variations.
We also identify distinct features on the structure of the
variables and individual metabolic components in the switch
from normoxia to hypoxia. Our results provide a framework
for future studies by integrating multi-omics data to predict
condition-specific metabolic phenotypes under hypoxia.
1. Introduction
In recent years, the use of metabolic models and their integration
with multi-omics data has been extensive in better understanding
the dynamics of disease processes [1]. Hypoxia, low-oxygen
tension, is a feature of most tumours, which arise from
uncontrolled proliferation of cancer cells. This microenvironment
upregulates the formation of angiogenic factors initiating
vascularization of the tumour cell [2]. Under this condition,
the rate of glycolysis is enhanced, resulting in increased lactate
production, while maintaining ATP levels and the biosynthesis of
building blocks, including nucleotides and protein synthesis.
2017 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.
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While metabolism has been seen merely as a marker for a long time, it is now widely accepted
that it constitutes a driver of cancer; all cancer cells exhibit altered metabolism. One altered
metabolic feature is an increased uptake of glucose through aerobic glycolysis, which is referred
to as ‘Warburg effect’ [3,4]. In most cancer cells, downstream glycolytic enzymes and glucose
transporters are overexpressed driven by hypoxia-inducible factor (HIF-1), along with oncogenes (such
as PI3K, Ras, mTOR and Akt) and loss of tumour suppressors (PTEN and p53) [4–6]. In addition
to over-simulating glycolytic enzymes, in rapidly growing tumours, HIF-1a regulates mitochondrial
pyruvate dehydrogenase (PDH) leading to metabolic reprogramming. Inhibition of PDH by HIF-
1a reduces mitochondrial respiration by reducing the flux of glucose to the tricarboxylic acid cycle
(TCA cycle) [7].
PDH is an important enzyme that links and controls the flux between glycolysis and the
TCA cycle. The PDH complex is a nuclear-encoded, mitochondrial matrix essential multi-enzyme
component that catalyses the irreversible conversion of pyruvate to acetyl-CoA. It is a member of
the α-ketoacid dehydrogenase complex family [8], which includes the α-ketoglutarate dehydrogenase
complex (KGDHC) and the branched-chain α-ketoacid dehydrogenase complex (BCDHC). The PDH
complex consists of three protein subunits: E1 (pyruvate dehydrogenase), E2, (dihydrolipoamide
acetyltransferase; DLAT) and E3, (dihydrolipoamide dehydrogenase; DLD). The E1 enzyme consists of
two alpha and two beta subunits; it is involved in removal of the carboxyl group from pyruvate and the
transfer of the acetyl group to the E2 enzyme [9]. E3 is common to all three α-ketoacid dehydrogenases.
These three subunits have distinct catalytic activity and depend on thiamine pyrophosphate (ThPP),
lipoamide and FAD as cofactors to catalyse the overall reaction, respectively [8]. PDH is highly regulated
through transcription factors and oncogenes in most cancers [4–7]. Cancer cells adopt their metabolism
to achieve their energetics demand. PDH regulates this adaptation by controlling glucose metabolism
and by linking glycolysis and the TCA cycle.
Metabolism is the only biological network that can be modelled reliably at a genome scale [10]. This
enables systems-level understanding of the mechanisms of disease factors and provides a unique insight
into the development of future therapies [11–14]. An increasing number of metabolic models (including
genome-scale models) have been reconstructed for human metabolism [15–19]. Furthermore, the number
of multi-omic integration methods to exploit such models is rapidly increasing [20,21]. Owing to
the growing numbers and size of metabolic models, Bayesian, machine-learning and optimization
techniques are being employed in this field to analyse and characterize metabolic features [10,22,23].
Given the critical role of PDH in controlling glucose flux between glycolysis and the TCA cycle and its
role in metabolic reprogramming in cancer cells, we model and investigate the role of PDH using a blend
of constraint-based modelling and machine-learning approaches. We develop a constraint-based model
of cancer metabolism and present the action of PDH, characterizing metabolic phenotypes seen during
hypoxia. We employ machine-learning methods to infer the reactions that contribute to the change in
the metabotype from normoxia to hypoxia. To the best of our knowledge, this is the first study to use
constraint-based modelling and machine-learning techniques to understand the metabolic role of PDH
under hypoxia.
2. Material and Methods
2.1. Construction and curation of the metabolic model
To simulate PDH complex activity during hypoxia, a model of human metabolism was constructed
based on the human metabolic model iAS253 [15]. The model was expanded based on interaction
networks to include additional mitochondrial matrix reactions. The MitoMiner database [24] was used
to find all proteins with evidence of mitochondrial localization. This information was supplemented
with annotation from UniProt [25] and the Gene Ontology [26]. MitoMiner was then used to find KEGG
reactions corresponding to each protein [27]. To confirm whether the new reactions are present in the
mitochondrial matrix and whether reactions should be added to the expanded model, each reaction
was manually examined by cross-referencing the information with BRENDA [28], HumanCyc [29] and
relevant literature. We chose to use this model over genome-scale models such as Recon 2 [18] because
small-scale models offer greater advantages for our application, particularly in enabling extensive
manual curation, easier interpretation of biological data and visualization of flux distributions. The
model is freely available in SBML format (see the electronic supplementary material, S1) for academic
use, and can be used to study cancer metabolism as well as other human metabolic disorders.
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Table 1. Comparison between IFEAS616 and Recon 2.
iFEAS616 Recon 2.2 [45]
reactions 826 7785
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
metabolites 765 5324
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
genes 332 1675
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2. Modelling pyruvate dehydrogenase using flux balance analysis
Flux balance analysis (FBA) is a widely used mathematical approach for modelling large-scale metabolic
networks [30]. Because FBA assumes the homeostasis of a system (constant internal metabolite
concentration x), it does not need knowledge of metabolite concentrations and enzyme kinetics. This
differentiates FBA from other modelling techniques that require kinetics parameters, usually are difficult
to obtain. In FBA, the set of biochemical reactions is represented mathematically in the form of a
stoichiometric matrix S; constraints are placed on individual reactions to limit the allowable flux ν each
reaction can carry. A unique solution is obtained by defining the objective function through a vector c;
this is a measure of how each component in the network contributes to the production of a biologically
desirable phenotype.
Formally, we adopt the following linear program:
max c · v, such that
S · v = x˙
Vmin ≤ v ≤Vmax
x˙i = 0 if Mi ∈ internal metabolites
x˙i ∈R if Mi ∈ exchange metabolites.
For a detailed description of FBA, we refer the reader to the work of Orth et al. [30]. To represent
the major role of the mitochondrion, primarily energy production, we used maximum ATP production
as the objective function. Linear programming was then used to calculate the optimal flux distribution
that maximizes the objective function. The model was encoded in SBML format [31] and fulfils MIRIAM
requirements [32]. Simulations were carried out in MATLAB (version R2016a) using the COBRA toolbox
[33] with the linear programming solver GLPK. All flux values were given in micromoles per minutes
per grams of dry weight (μmol min−1 gDW−1).
To represent hypoxia, the maximum allowable uptake flux of oxygen was reduced to
0 µmol min−1 gDW−1 in intervals of 10% from its level under normal conditions (19.8 μmol min−1 gDW−1).
The uptake value of 10% oxygen was chosen to reflect the typical conditions used in experimental
hypoxia studies [34–43]. For the first simulation, only the availability of oxygen was reduced while the
uptakes of metabolites into the system were kept unchanged [15]. Flux balance analysis was used to
determine effect of PDH and rate of ATP production during hypoxia.
To determine the effect of PDH on ATP production during hypoxia, the activity of PDH was reduced
from its maximum flux capacity to zero. It is well established that the concentration of some metabolites is
elevated during hypoxia in cancer cells. To further evaluate this, simulations were run where the uptake
of amino acids were unconstrained by increasing the upper uptake bound.
3. Results and discussion
A manually curated human metabolic model was created to model and investigate the metabolic
effects of PDH during hypoxia (see Material and methods). The model is composed of 616 reactions,
765 metabolites, 90 boundary reactions and 92 transport steps (electronic supplementary material,
S1). These transport steps represent the human mitochondria carrier family [44] and are modelled to
reflect the physiological role of each transport mechanism. Given the complexity of the role of PDH in
cancer metabolism, our model offers better advantages in interpretation of biological data and easier
visualization of flux data over genome-scale models such as Recon 2.2 (table 1).
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Figure 1. Effect of hypoxia on pyruvate dehydrogenase (PDH) and ATP production. (a) The flux of PDH was determined, when oxygen
availability was reduced from 100% (normoxia) to 0% (anoxia) of its normal value. To represent PDH effect onmetabolism seen in cancer
cells, uptake of amino acid was unconstrained (PDH+ AA). In all conditions, the rate of PDH gradually decreased as the availability of
oxygen decreased. (b) The rate of ATP production was determined by varying the flux of PDH from its maximum flux, while oxygen levels
were kept constant at 100%. A maximum ATP production flux of 138.1µmol min−1 gDW−1 was reached. For levels of PDH flux lower
than 9 µmol min−1 gDW−1, the ATP level declined regularly, with an increasing negative slope. (c) Under hypoxia, oxygen availability
was reduced to 10% of its normal value. ATP production increased above 17.2µmol min−1 gDW−1, but for activity of PDH lower than
1.8 µmol min−1 gDW−1, it decreased to 17µmol min−1 gDW−1. Interestingly, the decay observed in hypoxia is slower than in normoxia
conditions.
3.1. Pyruvate dehydrogenase mechanism under hypoxia
To determine PDH action under hypoxia, the maximum allowable uptake flux of oxygen was reduced
from normoxia (19.8 µmol min−1 gDW−1) to hypoxia (1.9 µmol min−1 gDW−1) in intervals of 10%. The
flux output of PDH gradually declined as the rate of oxygen availability was reduced from normoxia
to anoxia (figure 1a). Under these simulations, lactate and succinate accumulated at a rate of 1.04 and
0.59 µmol min−1 gDW−1, respectively (figure 2; electronic supplementary material, S2) consistent with
reports of hypoxia studies in the literature [34–43]. Succinate accumulated entirely from the TCA cycle as
an end-product of central metabolism, resulted from reduced capacity of the oxidative phosphorylation
(OXPHOS) to metabolize succinate.
Under aerobic respiration, succinate and electron-rich metabolites (such as NADH generated from the
TCA cycle and fatty acid oxidation) are oxidized by complexes II and I of the electron transport chain,
respectively. Oxidation of succinate (an intermediate of the TCA cycle) by complex II transfers electrons
to ubiquinone, a small lipid-soluble molecule that can be reduced and oxidized, and which freely
diffuses within and across the inner mitochondrial membrane. The reduced ubiquinol (UQH2) diffuses
to complex III where it is reoxidized; at the same time, complex III reduces cytochrome c, which in turn
reduces complex IV, where oxygen is used as terminal electron acceptor and reduced to water. The energy
from this chain of electron transfers is used by the respiratory complexes to transport protons across
the mitochondrial membrane, so generating the proton motive force and the electrochemical potential
across the mitochondrial membrane that is used by mitochondrial ATP synthase to form ATP from ADP
and phosphate. Under hypoxia, this mechanism diminishes owing to the lack of oxygen availability.
Therefore, the rate of succinate oxidation by OXPHOS is reduced, leading to its accumulation.
In our model, as expected, the majority of glycolytic-derived pyruvate was converted to lactate
(figure 2). The production of lactate allowed the removal of NADH generated from glycolysis owing
to the impaired capacity of the OXPHOS to oxidize NADH efficiently. This is consistent with the well-
known phenomena seen in cancer cells, namely that under hypoxia glycolytic rate is often enhanced
leading to increased production and accumulation of lactate [47]. Through this mechanism, glycolysis
maintains ATP levels and provides building blocks for nucleotide and protein synthesis, which is
essential in cancer cells to maintain proliferation through many transcription factors and oncogenes
[48,49].
Consistent with our findings, hypoxia directly increases lactate production and accumulation owing
to the effect of the changes in the mitochondrial redox status caused by reduced oxygen availability.
Under hypoxia, the NAD reduced : oxidized (NADH : NAD+) ratio in the mitochondria is high owing
to the reduced capacity of the electron transport chain and consequent reduction in the rate of NADH
oxidation by complex I [2]. Subsequently, this reduces NADH-producing reactions in the TCA cycle
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Figure 2. Metabolic map depicting glycolysis, the pentose phosphate pathway and TCA cycle during (a) normoxia and (b) hypoxia. The
flux distribution of central metabolism from simulation of normoxia and hypoxia is shown, where glycolysis starts from the uptake
of glucose from the extracellular compartment and its transport into the cytosol by glucose transporter. In the cytoplasm, glucose is
metabolized and converted to pyruvate and fed to the TCA cycle during normoxia. However, under hypoxia, the majority of glucose is
converted to lactate and exported to the extracellular compartment by lactate transporter, which in turn maintains the redox potential.
The flux distribution under both conditions is illustrated.We used Escher [46] to generate themetabolicmap, flux values for each reaction
are indicated. Line thickness and colour (grey to red) corresponds to the flux value. Negative flux values indicate the corresponding
reaction is operating in the reverse direction.
and oxidation of fatty acids, thereby reducing the transfer of glycolytic-derived NADH by the malate-
aspartate shuttle into the mitochondrial matrix. Thus, the production of lactate and its accumulation is
energetically favourable.
The production of lactate by lactate dehydrogenase (LDH), which leads to cellular acidification is
a contributing factor for the malignancy of cancer cells [50]. LDH consists of two subunits (LDHA
and LDHB); upregulation of LDHA through HIF1 results in pyruvate reduction in hypoxia [51,52].
In addition, HIF1 has been shown to upregulate almost all glycolytic genes encoding enzymes and
glucose transporters including hexokinase 1 and 3, aldolase A and C, and glyceraldehyde 3-phosphate
dehydrogenase, leading to metabolic reprogramming of glycolysis [51–54].
Furthermore, pyruvate dehydrogenase kinase 1 (PDK1) inhibits PDH during hypoxia leading
to reduced mitochondrial respiration and reactive oxygen species (ROS) production [55]. PDK1
phosphorylates and inhibits the PDH complex, reducing the conversion of pyruvate to acetyl-CoA,
thereby regulating the flux of metabolite to the TCA cycle. Our simulations, under both active and
inactive PDK1 activity during hypoxia (and normoxia) showed no change on the mechanism of PDH,
which should be considered an incorrect prediction of the model when maximum ATP production is used
as an objective function. This suggests that phosphorylation events can be introduced through metabolic
constraints, directly on the flux rates (e.g. through decreasing PDH flux as in figure 1) or through flux
bounds, e.g. shrinking upper and lower limits to simulate inhibition. Another possible approach could
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involve modifications of gene–protein–reaction rules of the PDH reaction to include PDK1, although this
would require the adoption of multi-omic extensions of FBA to simulate variable PDK1 activity levels.
Finally, further simulations were performed to determine whether additional sources of metabolites
enhanced PDH capacity. The uptake rate of amino acid metabolites in the model was unconstrained.
This enhanced PDH capacity by 29%, but as the levels of oxygen fell, PDH action decreased steadily
(figure 1a).
3.2. Pyruvate dehydrogenase action on ATP production
To determine whether PDH affects the rate of ATP production under normoxia and hypoxia, we
quantified ATP production while varying PDH in 10% decrement of its maximal flux. Figure 1b shows
a gradual decrease in ATP production when PDH flux was decreased. More specifically, the decrease of
PDH activity caused ATP production to decline only by 5% (from 138 to 131 µmol min−1 gDW−1). This
suggests that the majority of the source of ATP under normoxia is driven by alternative fuel sources,
including fatty acids. Under normal levels of oxygen availability, ATP production through OXPHOS was
primarily generated from β-oxidation of fatty acids, which generates energy-rich NADH and acetyl-CoA.
Acetyl-CoA subsequently enters the TCA cycle generating further electrons and succinate. The efficient
capacity of the electron transport chain then oxidizes NADH and succinate to generate ATP as described
above.
Under hypoxia (figure 1c), when oxygen was further reduced, the contribution of OXPHOS to ATP
production was gradually diminished. This was owing to the electron transport chain capacity to use
oxygen being restricted and its inability to use fatty acid as an energy source. Reduced capacity of
electron transport chain inhibits TCA cycle and NADH-producing reactions (including PDH) in the
mitochondrial matrix, such as fatty acid oxidation. Therefore, under this condition, the action of PDH
is reduced by 78% compared to conditions under normal oxygen supply, subsequently reducing the rate
of ATP production (figure 1b,c).
Under hypoxia, alternative carbon sources are used—amino acids, e.g. glutamine, lysine, proline and
valine. The mechanism in which glutamine (as a fuel source) enters central metabolism is as follows:
glutamine is converted in a two-step reaction to glutamate and then oxoglutarate by hydrolysing
glutamine to glutamate and ammonia (which accumulated) by glutaminase. Glutamate was imported
directly into the mitochondrial matrix and further converted to oxoglutarate and ammonia by glutamate
dehydrogenase. In the TCA cycle, oxoglutarate was converted to succinyl-CoA and then succinate,
subsequently used for ATP production. Consistent with this, under hypoxia, glutamine metabolism
maintains ATP synthesis through OXPHOS in tumour cells [56–58]. In addition, glutamate in cancer cells
activates reductive carboxylation through isocitrate dehydrogenase [59] and production of mitochondrial
NADPH through the activity of malic enzyme, a mitochondrial reaction which converts malate to
pyruvate, and is found to be expressed at high levels in some tumours [57].
3.3. Principal component analysis reveals hypoxia-versus-normoxia biomarkers
Machine learning in biology can be used to reveal unique characteristics from multidimensional and
high-throughput data [60,61]. Two broad types of methods exist in machine learning: supervised and
unsupervised learning. Unsupervised learning methods such as principal component analysis (PCA)
identify feature similarities in datasets. PCA is an eigenvector-based analysis that quantifies directions
that best explain variance in the data. In our case, it is based on the singular value decomposition (SVD)
of the flux rates, and is therefore equivalent to finding the system of axes in the space of flux rates such
that the covariance matrix is diagonal. PCA defines new variables, called principal components, as linear
combinations of the existing variables.
We performed PCA on the aggregate flux dataset from normoxia, hypoxia and hypoxia with
excess amino acid (HypoxiaAA) for all active reactions. Our goal was to identify key reactions that
drive variation and investigate how these drivers change over different levels of oxygen availability
(table 2 and figure 3a–e). The principal components always represent an orthogonal basis of the space
of flux rates.
Using PCA on our flux dataset showed that the first two eigenvectors sum to more than 98% of
the variance in the dataset (figure 3a,b). This indicates that changes in reaction fluxes are correlated
under various levels of oxygen, and the changes following the uptake of additional amino acids are
also correlated (table 2a). Plotting the first two singular vectors of PCA on the fluxes shows distinct
features on the structure of the variable and individual components (figure 3a,c). We found that the
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Figure 3. Principal component analysis of flux rates. (a) Individual factor map. Biomass5 (ATP production) and some reaction of OXPHOS
(i.e. R00086MM and R02163MM) are distinguishable between the different conditions, and therefore constitute the main metabolic
biomarkers of hypoxia. (b) Correlation histogram. Toppanel shows significance level (p-value< 0.001) associatedwith the corresponding
correlation coefficients. Diagonal panel shows the distribution of each variable. (c) Variables factor map. The first component (Dim1)
correlates almost perfectly with the variable hypoxia, while the second component correlates mostly with HypoxiaAA. (d) Scree plot
generated from eigenvalue versus component number. (e) Correlation matrix illustrating the correlation between each variable. Positive
correlation is displayed by a blue colour, while the colour intensity and size of the circles are proportional to the correlation coefficients.
The reader is referred to the electronic supplementary material, S1 for individual reaction names, and to the main text for further details
and interpretations.
Table 2. Contribution of variables and individual reactions on the principal components. (The variable hypoxia is highly correlated with
thefirst component (PC1), compared to variableHypoxiaAA. This variation is drivenby excess amino acids present inHypoxiaAA in addition
to the lack of oxygen. The individual reactions on the first two principal components showoxygen transporter (reaction id: Transporter47)
and to some extent ATP production (reaction id: BioMass5) scored highly, indicating a significant effect on ATP synthase activity (see text
for a more detailed description).)
condition PC 1 PC 2 PC 3
(a)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
normoxia 0.979 −0.185 0.083
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
hypoxia 0.991 −0.076 −0.108
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HypoxiaAA 0.963 0.267 0.027
reaction ID reaction description PC 1 PC 2 PC 3
(b)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Transporter47 oxygen transporter 16.486 6.859 1.170
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BioMass5 ATP production 17.570 0.360 0.259
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
R00086MM ATP synthase 13.241 0.162 1.401
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
R02161MM complex III 0.823 1.175 0.132
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
R02163MM complex I 1.343 1.685 0.653
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Boundary2 oxygen uptake 0.198 0.305 0.030
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
first component (figure 3d, Dim1) correlates highly with variable hypoxia, while the second component
correlates with the variable HypoxiaAA. The variation in each condition is driven by changes in addition
to the amount of oxygen but also by the excess amino acids present in HypoxiaAA (table 2a). Addition
of metabolites such as glutamine and arginine increased the rate of ATP production during hypoxia, by
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enhancing the availability of substrates (and electrons) required for energy generation. Figure 3a and
table 2b show the individuals factor map plot of the principal component scores for individual reactions
on the first two principal components. Superimposed on the plot are mean scores on the components for
qualitative variables that are included in the PCA. The reactions ATP synthase (reaction id: R00086MM)
and HypoxiAA ATP production (reaction id: BioMass5) scored highly with the first component, therefore
indicating a large impact of ATP synthase activity in determining the normoxic or hypoxic phenotype.
Our results are in keeping with the fact that ATP synthase is highly dependent on the rate of oxygen
and metabolite availability for generating ATP. In fact, the mechanism by which ATP is generated is as
follows and depends on molecular oxygen under normal conditions. Oxidation of glucose begins with
glycolysis in the cytoplasm generating NADH, ATP and pyruvate. Pyruvate is then transported into
the mitochondrial matrix and is converted to acetyl-CoA and NADH by PDH. Subsequently, acetyl-
CoA enters the TCA cycle and is oxidized to CO2 and water, yielding NADH and GTP. Electron-rich
metabolites such as NADH generated from these pathways and oxidation of fatty acids, together with
succinate HypoxiaAA are then oxidized by complexes I and II, respectively. As described above, the
transfer of these electrons generates the electrochemical gradient across the mitochondrial membrane,
which in turn is used by ATP synthase to form ATP.
4. Conclusion
The PDH complex regulates the metabolic adaptation by controlling glucose metabolism, used by
cancer cells to meet the bioenergetics demands. To investigate the complexity of role of PDH in cancer
metabolism, we used a small-scale constraint-based model; the choice of our model over genome-scale
model was appropriate for in-depth interpretation of biological results.
Our results showed PDH action diminished during hypoxia. We identified metabolic markers of
cancer metabolism (lactate production and its accumulation) in agreement with experimental findings
in the literature. Taken together, the combination of our model, machine learning results and known
biochemistry suggests that oxygen transporters and ATP synthase and production constitute clear
biomarkers of hypoxic behaviour.
We envisage that our model will be useful to researchers for studying human diseases involving a
hypoxia-like metabotype, including cancer. To expand and further investigate such diseases, the model
can be used as a scaffold to integrate multi-omics data [61,62], and to predict condition-specific metabolic
configurations, e.g. by dynamically changing flux bounds using transcriptomic and proteomic data.
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